Pilot open label study of MD1003 (biotin) in the treatment of Progressive Multiple Sclerosis

Trial Profile

Pilot open label study of MD1003 (biotin) in the treatment of Progressive Multiple Sclerosis

Completed
Phase of Trial: Phase II

Latest Information Update: 22 Apr 2015

At a glance

  • Drugs Biotin (Primary)
  • Indications Multiple sclerosis
  • Focus Adverse reactions; Proof of concept; Therapeutic Use
  • Most Recent Events

    • 22 Apr 2015 New trial record
    • 17 Apr 2015 According to MedDay Pharmaceuticals media release, the results were published in the Journal of Multiple Sclerosis and Related Disorders.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top